Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Minal A Barve"'
Autor:
Nirav N. Shah, Michael Wang, Lindsey E. Roeker, Krish Patel, Jennifer A. Woyach, William G. Wierda, Chaitra S. Ujjani, Toby A. Eyre, Pier Luigi Z inzani, Alvaro J. Alencar, Paolo Ghia, Nicole Lamanna, Marc S. Hoffmann, Manish R. Patel, Ian Flinn, James N. Gerson, Shuo Ma, Catherine C. Coombs, Chan Y. Cheah, Ewa Lech-Maranda, Bita Fakhri, Won Seog Kim, Minal A. Barve, Jonathon B. Cohen, Wojciech Jurczak, Talha Munir, Meghan C. Thompson, Donald E. Tsai, Katherine Bao, Nicholas A. Cangemi, Jennifer F. Kherani, Richard A. Walgren, Hongmei Han, Amy S. Ruppert, Jennifer R. Brown
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase 1/2 BRUIN study evaluated pirtobrutinib, a highly selective non-covalent (reversible) BT
Externí odkaz:
https://doaj.org/article/14e14931fbe749748bffaa96d517c4bb
Autor:
Lydia Scarfò, Manish R. Patel, Toby A. Eyre, Wojciech Jurczak, David Lewis, Thomas Gastinne, Shuo MA, Jonathon B. Cohen, Krish Patel, Jennifer R. Brown, Talha Munir, Ewa Lech-Maranda, Marc S. Hoffmann, Chaitra S. Ujjani, Bita Fakhri, Michael Wang, Koji Izutsu, Hirokazu Nagai, Constantine S. Tam, John F. Seymour, Joanna Rhodes, Julie Vose, Matthew Mckinney, James N. Gerson, Minal A. Barve, Bryone Kuss, Youngil Koh, Wei Gao, Amy S. Ruppert, Richard A. Walgren, Donald E. Tsai, Binoj Nair, Katherine Bao, Anthony R. Mato, Chan Y. Cheah, M Lia Palomba
Publikováno v:
HemaSphere, Vol 7, p e852670f (2023)
Externí odkaz:
https://doaj.org/article/a040220921ef4307b9e157dc91a3150b
Autor:
M.Lia Palomba, Manish R. Patel, Toby A. Eyre, Wojciech Jurczak, David John Lewis, Thomas Gastinne, Shuo Ma, Jonathon B. Cohen, Krish Patel, Jennifer R. Brown, Lydia Scarfò, Talha Munir, Ewa Lech-Marańda, Marc Hoffmann, Chaitra S. Ujjani, Bita Fakhri, Michael L. Wang, Koji Izutsu, Hirokazu Nagai, Constantine S. Tam, John F. Seymour, Joanna M. Rhodes, Julie M. Vose, Matthew McKinney, James N. Gerson, Minal A. Barve, Bryone J. Kuss, Youngil Koh, Wei Gao, Amy S. Ruppert, Richard A. Walgren, Donald E. Tsai, Binoj Nair, Katherine Bao, Anthony R. Mato, Chan Y. Cheah
Publikováno v:
Blood. 140:557-560
Autor:
Nirav N. Shah, Michael L. Wang, Jennifer R. Brown, Krish Patel, Jennifer A. Woyach, William G. Wierda, Chaitra S. Ujjani, Toby A. Eyre, Pier Luigi Zinzani, Alvaro J. Alencar, Thomas Gastinne, Paolo Ghia, Nicole Lamanna, Marc Hoffmann, Manish R. Patel, Ian W. Flinn, James N. Gerson, Shuo Ma, Catherine C. Coombs, Chan Y. Cheah, Ewa Lech-Marańda, Bita Fakhri, Won-Seog Kim, Minal A. Barve, Jonathon B. Cohen, Wojciech Jurczak, Talha Munir, Meghan C. Thompson, Lindsey E. Roeker, Katherine Bao, Nicholas A. Cangemi, Jennifer F. Kherani, Richard A. Walgren, Hongmei Han, Amy S. Ruppert, Anthony R. Mato
Publikováno v:
Blood. 140:4127-4132
Autor:
Santosh Kesari, Alberto Bessudo, Brian R Gastman, Anthony P Conley, Victoria M Villaflor, Lisle M Nabell, DeLisa Madere, Emma Chacon, Christina Spencer, Li Li, Christopher Larson, Tony Reid, Scott Caroen, Bryan Oronsky, Meaghan Stirn, Jeannie Williams, Minal A Barve
Publikováno v:
Future Oncology. 18:3245-3254
AdAPT-001 is an investigational therapy consisting of a replicative type 5 adenovirus armed with a TGF-β receptor-immunoglobulin Fc fusion trap, designed to neutralize isoforms 1 and 3 of the profibrotic and immunosuppressive cytokine, TGF-β. In pr
Autor:
Sai-Hong Ignatius Ou, Pasi A. Jänne, Ticiana A. Leal, Igor I. Rybkin, Joshua K. Sabari, Minal A. Barve, Lyudmila Bazhenova, Melissa L. Johnson, Karen L. Velastegui, Cornelius Cilliers, James G. Christensen, Xiaohong Yan, Richard C. Chao, Kyriakos P. Papadopoulos
Publikováno v:
Journal of Clinical Oncology. 40:2530-2538
PURPOSE Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRASG12C. We report results from a phase I/IB study of adagrasib in non–small-cell lung cancer, colorectal cancer, and other solid tumors harboring the
Autor:
Brian A. Van Tine, Monica Mita, Minal A. Barve, Erika P. Hamilton, Andrew J. Brenner, Frances Valdes, Daniel Ahn, Joleen Hubbard, Jason Starr, Angela Georgy, Joshua Pelham, Banmeet S. Anand, Thomas Strack, Andrés Machado Sandri, Zev A. Wainberg
Publikováno v:
Cancer Research. 82:P2-13
Background: Engineered toxin bodies (ETBs) are composed of a de-immunized Shiga-like Toxin A subunit genetically fused to an antibody-like binding domain. ETBs can force receptor internalization, induce potent cell-kill via enzymatic and permanent in
Autor:
Susan E. Morgan-Lappe, Zev A. Wainberg, Ramesh K. Ramanathan, Huibin Yue, Martha Elizabeth Blaney, Louie Naumovski, John H. Strickler, Lan Wang, John Nemunaitis, George W. Sledge, Erika Hamilton, Sreeneeranj Kasichayanula, Minal A. Barve, Michael S. Gordon, Monica Motwani
Publikováno v:
Molecular cancer therapeutics, vol 20, iss 10
Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from a phase I s
Autor:
William Jeffery Edenfield, Daniel Da Costa, David Hoffman, Matthew P. Kosloski, Minal A. Barve, Scott A. Laurie, Alexander Starodub, Jonathan W. Goldman, Satwant Lally, Martina M. Koch, Afshin Dowlati, Antoinette J. Wozniak, Jyoti D. Patel, Grace K. Dy, Taofeek K. Owonikoko
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 2, Pp 664-670 (2021)
Clinical and Translational Science
Clinical and Translational Science
Small cell lung cancer (SCLC) is a leading cause of cancer death worldwide, with few treatment options. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate that targets delta-like 3 on SCLC cells to deliver a cytotoxic payload directly to
Abstract PS11-28: Efficacy and safety of entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer
Autor:
Janice Lu, Todd M. Bauer, Minal A. Barve, S. Osborne, Filippo de Braud, Tira Tan, Christophe Le Tourneau, B. Simmons, Alexander I. Spira, Samuel McCallum, Collin M. Blakely, Saiama N. Waqar, David S. Hong
Publikováno v:
Cancer Research. 81:PS11-28
Neurotrophic tyrosine receptor kinase genes (NTRK1/2/3) act as oncogenic drivers across a range of tumors. NTRK fusions occur at low frequency (90% of secretory breast carcinomas. Furthermore, up to 30% of patients (pts) with breast cancer will devel